MENU
Logo Made in Germany BIO 2018

Morphosys AG

Booth number: 1401-2

www.morphosys.com
bd@morphosys.com

About us

MorphoSys is a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on our proprietary technology platforms and leadership in the field of therapeutic antibodies, we, together with our partners, participate in the development of more than 100 therapeutic product candidates currently in R&D, 28 of which are in clinical development. Our broad pipeline spans two business segments: Proprietary Development, in which we invest in and develop product candidates, and Partnered Discovery, in which we generate product candidates for our partners in the pharmaceutical and biotechnology industries against targets identified by our partners.



Products and services

MOR208—pivotal stage Fc-engineered humanized monoclonal antibody directed against CD19 for B-cell lymphomas. MOR208 is currently in clinical investigation in three combination studies. MOR208 in combination with lenalidomide received breakthrough designation in October 2017 for the treatment of transplant-ineligible patients with r/r DLBCL.

MOR202—an investigational, human monoclonal HuCAL antibody directed against CD38. MOR202 has completed recruitment in a Phase 1/2a trial in patients with relapsed or refractory multiple myeloma (r/r MM). The study is evaluating the safety and preliminary efficacy of MOR202 alone and in combination with the immunomodulatory drugs pomalidomide or lenalidomide, plus dexamethasone, respectively.

MOR106—a human monoclonal antibody targeting IL-17C, is currently under clinical development for the treatment of atopic dermatitis. MOR106 is also the first antibody from our Ylanthia platform that entered clinical development.

MOR208

MOR208

pivotal stage Fc-engineered humanized monoclonal antibody directed against CD19 for B-cell lymphomas. MOR208 is currently in clinical investigation in three combination studies. MOR208 in combination with lenalidomide received breakthrough designation in October 2017 for the treatment of transplant-ineligible patients with r/r DLBCL.

www.morphosys.com/pipeline/proprietary-portfolio/mor208

MOR202

MOR202

an investigational, human monoclonal HuCAL antibody directed against CD38. MOR202 has completed recruitment in a Phase 1/2a trial in patients with relapsed or refractory multiple myeloma (r/r MM). The study is evaluating the safety and preliminary efficacy of MOR202 alone and in combination with the immunomodulatory drugs pomalidomide or lenalidomide, plus dexamethasone, respectively.

www.morphosys.com/pipeline/proprietary-product-portf...

MOR106

MOR106

a human monoclonal antibody targeting IL-17C, is currently under clinical development for the treatment of atopic dermatitis. MOR106 is also the first antibody from our Ylanthia platform that entered clinical development.

www.morphosys.com/pipeline/proprietary-portfolio/mor106

News & Innovations

MorphoSys Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-Term Skin Clearance In Patients With Moderate-To-Severe Plaque Psoriasis 

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen) reported data from the Phase 3 VOYAGE 2 study of TREMFYA(R) (guselkumab), which demonstrated long-term skin clearance in patients with moderate to se...| » Further reading 


MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab 

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and I-Mab announced today that they have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao. MOR202 is MorphoSys's proprietary investigational antibody...| » Further reading 


MorphoSys and Galapagos Present Results from a Phase 1 Study with MOR106 in Atopic Dermatitis as Late-Breaking Abstract at the American Academy of Dermatology (AAD) Meeting in San Diego 

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext & NASDAQ: GLPG) announced the presentation of more detailed results of the Phase 1 study with the investigational IL-17C antibody MOR106 in AD patients at the American Academy of Dermatology (AAD) Annua...| » Further reading 


Contacts

Address
Morphosys AG
Semmelweisstr. 7
82152 Martinsried
Germany

Phone: +49 89 89927453

Sandra Rengsberger
Senior Team Assistant
Phone: +498989927453
bd@morphosys.com


Business matching
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.

Click here if you notice an image that violates copyright or privacy rights.

Your personal organizer

Your personal organizer

Print list  |  Save as PDF
This is your personal organizer to manage your contacts to the German exhibitors.